Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Health Claims Guidance Chilling For Consumers’ Options – AAHF

This article was originally published in The Tan Sheet

Executive Summary

A group promoting greater access to alternative medicines says FDA's proposed evidence-based review system for industry to evaluate health claims poses "grave consequences" for consumers seeking options to medication for their health care

You may also be interested in...



FDA Health Claims Draft Guidance Should Value Totality Of Evidence – CRN

FDA's apparent contention that results from randomized controlled trials invalidate conflicting information from observational studies on the effects of nutrients reflects "an intrinsic bias" within the agency or "a lack of fundamental understanding of research methods," according to the Council for Responsible Nutrition

FDA Tackles Observational Studies In Draft Health Claims Guidance

"Scientific conclusions from observational studies cannot be drawn about a relationship between a food component and a disease," FDA concludes in draft guidance for health claim petitioners

FDA On Lookout For “Shenanigans” In Nutritionals – Consultant

More FDA enforcement action is focusing on regulatory compliance by nutritional supplement firms in part because there is "plenty of room for shenanigans" in marketing the products, according to John Avellanet, a compliance consultant

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS100951

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel